PO.CH01.01 · 化学
Targeted Protein Degradation and Induced Proximity
-
-
-
-
- 5154 5154 蛋白水解与基因沉默靶向嵌合体（PROGENTAC） Proteolysis and gene silencing targeting chimera (PROGENTAC) Abhay Prasad, Rong Zheng, Deeksha Satyabola, Yang Xu, Yichen Yan, Hao Yan
-
-
- 5158 5158 HY809382的临床前表征：一种高效、口服生物利用度高的PRC2 PROTAC，用于治疗淋巴瘤和实体瘤 Preclinical characterization of HY809382, a highly potent and orally bioavailable PRC2 PROTAC, for the treatment of lymphoma and solid tumors Huangtao Jin, Juan Du, Ruwei Wang, Zengrong Li, Ting Zhang, Xing Yu, Ming Weng, Xiaoxiao Wang, Xiaohong Hou, Feifei Yang, Xin Li, Weixing Zhu, Liming Zhang, Lei Chen, Sai Yang, Feng Xu, Qian Ma, Ruowen Zhang, Xiaotian Huang
-
- 5161 5161 HJ-004：一种强效、选择性的泛EGFR突变靶向蛋白降解剂（TPD），可有效克服EGFR突变型NSCLC中的奥希替尼耐药 HJ-004, a potent and selective pan-EGFR mutation targeted protein degrader (TPD) that effectively overcomes osimertinib resistance in EGFR-mutant NSCLC Li Zeng, Yao Liu, Ya Geng, Yue Zhu
-
-
- 5166 5166 NRX-4972，一种选择性口服Aurora激酶A降解剂，在SCLC肿瘤模型中表现出更高的疗效，并显示出比AURKA抑制剂更强的体外协同作用 NRX-4972, a selective, oral, Aurora kinase A degrader, demonstrates increased efficacy in an SCLC tumor model, and greater in vitro synergy than an AURKA inhibitor Hua Tian, Ryan B. Rountree, Jeffrey T. Mihalic, Eric R. Wegrzyniak, Ge Wei, Karthik Arumugam, Paul L. Auger, Graham J. Carlson, Robert T. Cass, Tarra Knotts, Filippo Marchioni, Daniel Medina-Cleghorn, Michael G. Mormino, Madeleine P. Nemchek, Rusha M. Sardhara, Sangita Sridharan, Austin Tenn-McClellan, Simon Vezina-Dawod, Gwenn M. Hansen
-
-
-
-
- 5171 5171 EGFR-PROTAC分子TY-2719减弱对第三代EGFR TKI的获得性耐药并增强KRAS突变体抑制剂在实体瘤中的疗效 The EGFR-PROTAC molecule TY-2719 attenuates acquired resistance to 3rd-generation EGFR TKIs and augments the efficacy of KRAS mutant inhibitors in solid tumors Apeng Liang*, #, Shengli Dong*, #, Shaoqing Chen*, Hongqiang Li, Zhiyong He, Zhengfei Guo, Meihua Li, Shunxun Han, Guangbin Liu, Xi Wang, Yanyan Liu, Ling Fang, Yi Long, Xiang Zhang, Wei Wu, Chengshan Niu, Jun Li, Yusheng Wu
-
- 5173 5173 靶向SALL4致癌基因的小分子降解剂的鉴定 Identification of a small molecule degrader targeting SALL4 oncogene Kim Anh L. Vu, Shiva Moein, Kalpana Kumari, Bee Hui Liu, Miao Liu, Chong Gao, Li Feng, Mahmoud Bassal, Douglas Auld, Dominik Casalena, Qiling Zhou, Daniel G. Tenen, Li Chai
-
- 5175 5175 用于治疗SMARCA4突变型癌症的每月一次静脉给药及口服可生物利用的SMARCA2降解剂的发现与表征 Discovery and characterization of once in a month intravenous and orally bioavailable SMARCA2 degraders for treating SMARCA4 mutant cancers Bilash Kuila, Kiran B. Aithal, Sandeep Vitthal Dukare, Charamanna KB, Khaji Abdul Rawoof, Prasath Kothandaraman, Amit A. Dhudashiya, Nandish C, Payel Das, Anuradha Gadeval, Madhu K L, Bhagwan Mahadeo Dhaytadak, Gopinath CH, T Jagadeesh Kumar, Suraj Tgore, Mohamad Fairus Bin Abdul Kadir, Leena Khare, Ranadeep Bokalial, Samiulla DS, Subhendu Mukherjee, Saravanan Thiyagarajan, Kavitha Nellore, Rajesh Eswarappa, Girish Daginakatte, Chandrasekhar Abbineni, Sanjeev Giri, Murali Ramachandra, Susanta Samajdar
-
-
-
-
-
